Microbial process for preparing pravastatin

Abstract:

The present invention relates to a new microbial process for the preparation of the compound formula (I) ##STR1## from a compound of general formula (II) ##STR2## wherein R stands for an alkali metal or ammonium ion, by the submerged cultivation of a mold strain able to 6.beta.-hydroxylate a compound of the Formula (II) in aerobic fermentation and by the separation and purification of the product of Formula (I) formed in the course of the bioconversion. The process comprises cultivating a strain of Mortierella maculata filamentous mold species that is able to 6.beta.-hydroxylate a compound of the general Formula (II), on a nutrient medium containing assimilable carbon and nitrogen sources and mineral salts and separating the product formed from the fermentation broth, then isolating the compound of formula (I) and purifying the same. Novel strains of Mortierella maculata are also disclosed.

Citations
4346227 4537859 5064817 5130130
Cited By
Patent number     Title Issue date
7001919 Forms of pravastatin sodium 2006-02-21
Suggestions

If you were to search for Microbial process for preparing pravastatin using relaxed search criteria, these patents would come up:

Patent number     Title Issue date
6169189 Process for preparing tetrahydrofuran from dialkoxybutenes 2001-01-02
6171571 Crystalline multinary metal oxide compositions, process for preparing and processes for using the composition 2001-01-09
6171573 Alumina sol, process for preparing the same, process for preparing alumina molding using the same, and alumina-based catalyst prepared thereby 2001-01-09
6171958 Process for preparation of diffusion barrier for semiconductor 2001-01-09
6172008 Process for preparing high crystallinity oxide thin film 2001-01-09
6172012 Titanium complex grease composition including performance additives and process for preparation thereof 2001-01-09
6172015 Polar monomer containing copolymers derived from olefins useful as lubricant and fuel oil additives, processes for preparation of such copolymers and additives and use thereof 2001-01-09
6172121 Process for preparing organoclays for aqueous and polar-organic systems 2001-01-09
6261619 Noncarbonated beverage products with improved microbial stability and processes for preparing 2001-07-17
6268003 Noncarbonated beverage products with improved microbial stability and processes for preparing 2001-07-31
6294214 Noncarbonated beverage products with improved microbial stability and processes for preparing 2001-09-25
6368819 Microbial process for the preparation of acetic acid as well as solvent for its extraction from the fermentation broth 2002-04-09
6613550 Microbial process for preparation of optically active 3-hydroxypyrrolidine derivatives 2003-09-02
6682913 Microbial process for preparing pravastatin 2004-01-27
6696599 Microbial process for preparing pravastatin 2004-02-24
7141245 Process for preparation of a microbial agent 2006-11-28
6750366 Microbial process for preparing pravastatin 2004-06-15
6753170 Microbial process for the preparation of acetic acid, as well as solvent for its extraction from the fermentation broth 2004-06-22
7196218 Microbial process for the preparation of acetic acid, as well as solvent for its extraction from the fermentation broth 2007-03-27
7223590 Process for preparing pravastatin sodium 2007-05-29
Claims:

We claim:

1. A microbial process for the preparation of a compound of formula (I) ##STR6##

from a substrate of formula (II) ##STR7##

wherein R stands for an alkali metal or ammonium ion, comprising the steps of a) cultivating a strain of Mortierella maculata filamentous mold species able to 6.beta.-hydroxylate a compound of formula (II) on or in a nutrient medium containingassimilable carbon- and nitrogen sources and mineral salts, b) feeding the substrate to be transformed into the culture of Mortierella maculata, c) fermenting the substrate until the end of bioconversion, and d) isolating the compound of formula (I) fromthe culture.

2. The process of claim 1 wherein the strain of Mortierella maculata is cultivated at about 25.degree. C. to 30.degree. C.

3. The process of claim 2 wherein the hydroxylase activity of the Mortierella maculata is induced by exposure to 8-de-(2-methylbutyryl)-compactin or compactin during cultivation.

4. The process of claim 1 wherein the strain of Mortierella maculata is the Mortierella maculata n. sp. E-97 strain deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the number NCAIM(P)F001266.

5. The process of claim 1 wherein the strain of Mortierella maculata is the Mortierella maculata n. sp. E-97/15/13 strain deposited at the National Collection of Agricultural and Industrial Microorganisms, Budapest, Hungary under the numberNCAIM(P)F 001267.

6. The process of claim 1 wherein a source of assimilable carbon selected from the group consisting of glucose, fructose and glycerine is added to the culture.

7. The process of claim 1 wherein a source of assimilable nitrogen selected from the group consisting of soybean meal, peptone, casein, yeast extract and meat extract is added to the culture.

8. The process of claim 1 wherein the nutrient medium is a liquid culture broth.

9. The process of claim 8 wherein the substrate is fed into the culture broth when the pH of the culture broth is equal to or greater than 6.3 and wherein the substrate is fed into the culture broth contemporaneously with addition of a source ofassimilable carbon and wherein the amount of the source of assimilable carbon that is added is about 1% by weight per volume of the culture broth if the pH is higher than 6.7, and wherein the amount of the source of assimilable carbon that is added isabout 0.5% by weight per volume of the culture broth if the pH is within the range of 6.3 to 6.7.

10. The process of claim 8 wherein the isolating comprises separating pravastatin free acid from the liquid culture broth by adsorption on an anionic ion exchange resin.

11. The process of claim 8 wherein the isolating comprises: a) extracting pravastatin free acid from the culture broth into a water immiscible organic solvent, b) either lactonizing the pravastatin free acid or converting the pravastatin freeacid to a secondary amine salt, and c) converting the lactone or secondary amine salt to the compound of formula (I).

12. The process of claim 11 wherein the culture broth is adjusted to pH 3.5-3.7 before extracting the culture broth with the water-immiscible organic solvent.

13. The process of claim 12 wherein the water-immiscible organic solvent is ethyl acetate.

14. The process of claim 12 wherein the water immiscible organic solvent is isobutyl acetate.

15. The process of claim 8 wherein isolating the compound of formula (I) comprises: a) extracting the culture broth with a water-immiscible organic solvent, b) contacting the organic extract with an alkaline aqueous solvent containing sodium toform the compound of formula (I) as a solute in the aqueous solvent, and c) purifying the compound of formula (I) by chromatography on a non-ionic adsorbing resin.

16. The process of claim 15 wherein the alkaline aqueous solvent containing sodium is aqueous sodium hydroxide.

17. The process of claim 8 wherein isolating the compound of formula (I) comprises: a) filtering the culture broth, b) loading the filtered culture broth onto an anionic exchange resin, c) eluting pravastatin free acid from the resin, d)lactonizing the pravastatin free acid, e) isolating pravastatin lactone, f) hydrolyzing the lactone with sodium hydroxide to form the compound of formula (I), and g) purifying the compound of formula (I) by chromatography on a non-ionic adsorption resin.

18. The process of claim 17 wherein the anion exchange resin has quaternary ammonium active groups carried on a polystyrene-divinylbenzene skeleton.

19. The process of claim 8 wherein the substrate is fed into the culture broth when the pH of the culture broth is equal to or greater than 6.3, and wherein a sufficient amount of assimilable carbon is added to the culture broth to maintain thepH at about 6.3 to about 6.7.

20. The process of claim 19 wherein the assimilable carbon consists essentially of glucose.

21. The process of claim 12 wherein the pravastatin free acid is converted to a secondary amine salt and the converting of the pravastatin free acid to a secondary amine salt comprises: a) adding a secondary amine containing alkyl-, cycloalkyl-,aralkyl- or aryl substituents to the water-immiscible organic solvent after the extracting, and b) precipitating the secondary amine salt of pravastatin.

22. The process of claim 21 wherein converting the secondary amine salt to the compound of formula (I) comprises: a) suspending the precipitated secondary amine salt of pravastatin in a mixture of water and an ester having the formula CH.sub.3COOR', where R' is an alkyl group containing 1-4 carbon atoms, b) contacting an aqueous solution of sodium hydroxide with the suspension, c) washing the aqueous solution with isobutyl acetate, d) clarifying the aqueous solution with activated carbon, ande) lyophilizing the solution to obtain the compound of formula (I).

23. The process of claim 22 wherein the 1-4 carbon atom-containing alkyl ester is isobutyl acetate.

24. The process of claim 22 wherein converting the secondary amine salt to the compound of formula (I) further comprises purifying the compound of formula (I) to at least 99.5%, as measured by HPLC, using gel chromatography.

25. The process of claim 21 wherein converting the secondary amine salt to the compound of formula (I) further comprises: a) suspending the precipitated secondary amine salt of pravastatin in a 1-4 carbon atom-containing alcohol, b) adding asufficient amount of ethanolic solution of sodium hydroxide to the suspension to dissolve the secondary amine salt of pravastatin, c) adding acetone to the resulting solution to precipitate the compound of formula (I), and d) separating the compound offormula (I).

26. The process of claim 25 wherein the 1-4 carbon atom-containing alcohol is ethanol.

27. The process of claim 21 wherein converting the secondary amine salt to the compound of formula (I) further comprises: a) dissolving the precipitated secondary amine salt of pravastatin in a mixture of a 1-4 carbon atom-containing alkyl esterof a 1-4 carbon atom-containing alkane carboxylic acid and a 1-4 carbon atom-containing alcohol, and b) adding sodium hydroxide to the resulting solution to precipitate the compound of formula (I), and c) separating the compound of formula (I).

28. The process of claim 27 wherein the mixture is a mixture of ethyl acetate and ethanol.

29. The process of claim 21 wherein the secondary amine is selected from the group consisting of dibenzyl amine, dicyclohexyl amine and dioctyl amine.

Patent number:
    6682913
View patent at USPTO

Filing date:
    February 3, 2000

Issue date:
    January 27, 2004

Inventors:
Istvan Barta (Budapest, HU)
Karoly Albrecht (Budapest, HU)
Ildiko Lang (Budapest, HU)
Sandor Boros (Szod, HU)
Gabor Ambrus (Budapest, HU)
Attila Andor (Budapest, HU)
Laszlo Birincsik (Miskolc, HU)
Gyula Horvath (Budapest, HU)
Margit Bidlo nee Igloy (Budapest, HU)
Eva Ilkoy (Budapest, HU)
Antonia Jekkel (Budapest, HU)
Attila Konya (Szolnok, HU)
Janso Salat (Budapest, HU)
Gyorgy Somogyi (Budapest, HU)
Julianna Mozes nee Suto (Budapest, HU)
Istvan Szabo (Budapest, HU)

Assignee:
Institute for Drug Research Ltd. (Budapest, HU)

Primary Examiner:
Irene Marx

Attorney, Agent or Firm:
Kenyon & Kenyon

Current U.S. Classification: 435/125 435/135 435/136 435/146 435/171

Email: contact@findthatpatent.com | © 2007 Dream Ratings | About

cool hit counter


example: magnesium alloy,  or: 6652852,  or: Jeffrey A. Ledbetter (inventor),  or whatever